Publications Nordic Urothelial Cancer Oncology Group Page ContentVingem trialVinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM). (External Link)Vinsor trialSafety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial. (External Link)Vinflunin-100 trial, 2016Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis. (External Link)Vintrex, 2017Combined treatment with pemetrexed and vinflunine in patients with metastatic urothelial cell carcinoma after prior platinum-containing chemotherapy - results of an exploratory phase I study. (External Link)OtherBest Practice, July 2018, Danish newsletter for physicians (External Link)Best Practice, October 2016, Danish newsletter for physicians (External Link)From Ph.d-projectsImproving chemotherapy in advanced urothelial cancer: real-world data studies and prospective clinical trials.Patient-reported outcomes in bladder cancer.Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease.Electronic reporting of patient-reported outcomes in a fragile and comorbid population during cancer therapy – a feasibility study.Patient-reported outcomes item selection for bladder cancer patients in chemo- or immunotherapy. (External Link)Quality of life in bladder cancer patients receiving medical oncological treatment; a systematic review of the literature. (External Link)Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder.(External Link)uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder-Possible Clinical Implications. (External Link)Patient-Reported Outcomes, Health-Related Quality of Life, and Clinical Outcomes for Urothelial Cancer Patients Receiving Chemo- or Immunotherapy: A Real-Life Experience. (External Link) Responsible editor Webgruppen på Rigshospitalet Please give your consent in order to send your message. Please enter a valid email address. Note: This mail is not secure. Your email should therefore not include civil registration numbers or health information.Read how to send secure digital post:https://www.regionh.dk/securemail Write your message: Write your email (Must be filled out): I hereby give my consent to the Capital Region of Denmark to process the information in my enquiry for professional purposes only. Read the terms for your consent Send No e-mail has been registred for this user/group